Arthneeti
All Q2 FY26 results →
D.

DexCom, Inc.

Q2 FY26Health Care Equipment and Supplies

DexCom, Inc. Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹72
Market cap₹27.9K Cr
P/E30.9
Updated29 May 2026
Read3 min read

What the Q2 FY26 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned

The short version

- 2026 revenue guidance reaffirmed at $5.16 billion to $5.25 billion, representing 11% to 13% organic growth (Page 4). - Growth expected to be fairly evenly split between U.S. - Full-year revenue guidance reaffirmed at $5.16 billion to $5.25 billion, representing 11% to 13% growth.

From DexCom, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Moderate growth
  • 2026 revenue guidance reaffirmed at $5.16 billion to $5.25 billion, representing 11% to 13% organic growth (Page 4).
  • Growth expected to be fairly evenly split between U.S. and international markets; U.S. comps tougher in early 2026 but easier later, international the reverse (Page 9).
  • Continued expansion through new product launches (e.g., G7 15 Day, Stelo internationally in 2026) and broadening insurance coverage (Page 3, 9).
  • Record global new patient starts in Q1 2026; U.S. new patient starts close to record (Page 6).
  • Long runway for U.S. CGM penetration as only ~30% of covered lives currently use CGM (Page 4).

2 more points from DexCom, Inc.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what DexCom, Inc. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • The company is continuing to invest in ramping up its manufacturing facility in Ireland, with expected increased spending in Q2 and Q3 as the facility becomes fully operational.
  • Investments in R&D are set to increase after a flat year-over-year Q1, including continued investment in Ireland.
  • The strategic focus on tuck-in M&A opportunities remains, particularly for geographic expansion or acquiring new capabilities.

2 more points from DexCom, Inc.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what DexCom, Inc. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what DexCom, Inc. said on order book & pipeline — free account, 30 seconds.

Continue your research

Others in Health Care Equipment and Supplies this season

  • Insulet Corporation (Q2 FY26)

    Insulet Corporation Q2 FY26 quarterly results analysis. Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24

  • Globus Medical, Inc. (Q2 FY26)

    Globus Medical, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $11,192, P/E 19.9. AI-powered earnings insights.

  • Align Technology, Inc. (Q2 FY26)

    Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap

  • Solventum Corporation (Q2 FY26)

    Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag

Compare:vs Intuitive Surgical, Inc.vs Stryker Corporationvs Medtronic plc

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

DexCom, Inc. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were DexCom, Inc. Q2 FY26 results?

- 2026 revenue guidance reaffirmed at $5.16 billion to $5.25 billion, representing 11% to 13% organic growth (Page 4). - Growth expected to be fairly evenly split between U.S. - Full-year revenue guidance reaffirmed at $5.16 billion to $5.25 billion, representing 11% to 13% growth.

What is DexCom, Inc. share price analysis?

DexCom, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 30.9 with a market cap of $27,914. Investors should review the full earnings analysis for detailed insights.

Is DexCom, Inc. planning capital expenditure?

- The company is continuing to invest in ramping up its manufacturing facility in Ireland, with expected increased spending in Q2 and Q3 as the facility becomes fully operational.

Keep DexCom, Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.